NL-OMON24020招募中不适用
Adalimumab dose reduction aiming low serum concentration with control of disease activity: a single blind, non-inferiority, randomised clinical trial
Reade Rheumatology Research Institute0 个研究点目标入组 89 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 89
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Rheumatoid arthritis patient, according to ACR 1987 ACR/EULAR 2010 criteria
- •Treated for at least 28 weeks with adalimumab
- •Adalimumab trough concentration >5mg/L
- •Who has agreed to participate (written informed consent);
- •Age 18 years or older.
排除标准
- •Scheduled surgery during the follow-up of the study or other pre-planned reasons for treatment discontinuation
- •Life expectancy shorter than follow-up period of the study;
- •No other disease that might flare if adalimumab is tapered like psoriasis, inflammatory bowel disease
研究者
相似试验
进行中（未招募）
1 期
Adalimumab dose reduction aiming low drug levels with control of disease activity (ADDORA-LOW)Rheumatoid arthritisEUCTR2019-001793-28-NLReade89
尚未招募
不适用
Adalimumab dose reduction aiming low serum concentration with control of disease activity (ADDORA-LOW) : a single blind, non-inferiority, randomised clinical trial10003816Rheumatoid arthritisNL-OMON55177Reade89
已完成
4 期
A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are OvertreatedPsoriasisNCT05683054University Hospital, Ghent19
终止
4 期
Dose Tapering Study of Adalimumab in PsoriasisPsoriasis VulgarisNCT04028713University Hospital, Ghent19
已完成
4 期
Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease ActivityRheumatoid ArthritisNCT04222920Reade Rheumatology Research Institute78